☆ 4.6 Article

The Kinetics of COVID-19 Vaccine Response in a Community-Vaccinated Population

JOURNAL OF IMMUNOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Microbiology

COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in Saliva

Pranay R. Randad et al.

Summary: This study found that salivary antibodies could be a noninvasive alternative for monitoring SARS-CoV-2 infection and seropositivity at a population scale. The results showed a high correlation between salivary and serum antibodies, and high sensitivity and specificity of salivary antibodies for detecting COVID-19 infection.

JOURNAL OF CLINICAL MICROBIOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19

Lauren B. Rodda et al.

Summary: The study found that individuals recovered from mild COVID-19 develop sustained SARS-CoV-2-specific immunological memory for at least 3 months, including immunoglobulin antibodies, neutralizing plasma, and memory B and T cells. These memory lymphocytes exhibit potent antiviral function, aiding in immune defense.

CELL (2021)

Add to Collection

Article Infectious Diseases

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Raches Ella et al.

Summary: The BBV152 vaccine demonstrated tolerable safety outcomes and enhanced immune responses in this clinical trial, leading to selection of both Algel-IMDG formulations for phase 2 immunogenicity trials. Further efficacy trials are warranted to validate the vaccine's effectiveness.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Jordan R. Barrett et al.

Summary: The study demonstrates that a booster dose of ChAdOx1 nCoV-19 is safer and better tolerated than priming doses. The booster dose significantly enhances anti-spike neutralizing antibody titers and other functional antibody responses. These data support the two-dose vaccine regime currently being evaluated in phase 3 clinical trials.

NATURE MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Alicia T. Widge et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Zijun Wang et al.

Summary: Volunteers who received the Moderna or Pfizer-BioNTech vaccine showed high levels of antibodies and memory B cell responses against SARS-CoV-2, with activity similar to individuals who had recovered from natural infection. However, their efficacy against specific SARS-CoV-2 variants was reduced, indicating a potential need for periodic updates to mRNA vaccines to maintain clinical efficacy.

NATURE (2021)

Add to Collection

Article Oncology

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Leticia Monin et al.

Summary: The study aimed to evaluate the safety and immunogenicity of the BNT162b2 vaccine in cancer patients. The results showed poor efficacy of a single vaccine dose in cancer patients, with significantly increased immunogenicity in solid cancer patients after a vaccine boost at day 21. Therefore, it is recommended to prioritize cancer patients for an early second dose on day 21.

LANCET ONCOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Development and validation of a quantitative, non-invasive, highly sensitive and specific, electrochemical assay for anti-SARS-CoV-2 IgG antibodies in saliva

Samantha H. Chiang et al.

Summary: The Amperial platform developed a highly specific and sensitive saliva assay for quantifying IgG antibodies to SARS-CoV-2, with validation of linearity, limit of detection, and establishment of a reference range. The saliva testing showed high concordance with plasma testing, indicating its potential as a non-invasive and population-based monitoring tool.

PLOS ONE (2021)

Add to Collection

Article Immunology

Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset

Tiandan Xiang et al.

Summary: One year after infection, most recovered patients still have detectable SARS-CoV-2-specific IgG antibodies, but only a minority have neutralizing activity, especially when facing specific mutated variants. This highlights the importance of vaccinations for individuals who have had a natural infection to protect against emerging variants.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Letter Oncology

Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment

Noa Eliakim-Raz et al.

JAMA ONCOLOGY (2021)

Add to Collection

Article Immunology

Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019

Juanjuan Zhao et al.

CLINICAL INFECTIOUS DISEASES (2020)

Add to Collection

Article Immunology

Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals

Ling Ni et al.

IMMUNITY (2020)

Add to Collection

Article Multidisciplinary Sciences

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Davide F. Robbiani et al.

NATURE (2020)

Add to Collection

Article Medicine, General & Internal

An mRNA Vaccine against SARS-CoV-2-Preliminary Report

L. A. Jackson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Ugur Sahin et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19

Kening Li et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Immunology

Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients

Baweleta Isho et al.

SCIENCE IMMUNOLOGY (2020)

Add to Collection

© Peeref 2019-2024. All rights reserved.